Indications
Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
Composition
- Active substance
- ritlecitinib tosilate
- International name (INN)
- ritlecitinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Litfulo
- Active substance
- ritlecitinib tosilate
- ATC code
- L04AF08
- Therapeutic area
- Alopecia Areata
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status
- Authorised